Tango Therapeutics (TNGX) investor relations material

Lead program and clinical progress

• Lead candidate TNG462, an MTA cooperative PRMT5 inhibitor, is advancing rapidly with data expected later this year.

• MTAP deletions, the target for TNG462, occur in 15–20% of solid tumors, especially in lung, pancreatic cancer, and glioblastoma.

• TNG462 has shown a median PFS of 24 weeks in late-line, difficult-to-treat cancers, with ORR in cholangiocarcinoma roughly double that of competitors.

• Upcoming data will focus on pancreatic cancer, with over 20 patients in both second and third line cohorts, each with at least six months of follow-up.

• Plans are in place for a registration trial in pancreatic cancer next year, with both monotherapy and combination strategies.

Competitive landscape and differentiation

• Main competitors are BMS and Amgen, with BMS seen as the primary rival; AstraZeneca and BeiGene are further behind.

• TNG462 is considered more MTAP selective and free of off-target toxicity compared to BMS, allowing higher dosing and potentially greater efficacy.

• BMS’s dose-limiting toxicities include seizures and rash, while TNG462’s are limited to on-target effects like anemia and thrombocytopenia.

• TNG462 achieves higher target coverage than BMS at comparable or higher doses.

• Durability of response is a key differentiator for PRMT5 inhibitors, with both TNG462 and BMS showing prolonged tumor control.

Pipeline expansion and future plans

• A brain-penetrant PRMT5 inhibitor, TNG5456, has entered the clinic, targeting glioblastoma with similar MTAP selectivity.

• The CoREST program is advancing, aiming to reverse resistance to checkpoint inhibitors in STK11-mutant lung cancer.

• Combination studies with RevMed’s RAS inhibitors (doroxonrasib and zoldonrasib) began in June, with rapid accrual and plans for dose expansion.

• Registration strategies include second-line monotherapy and first-line combinations, with flexibility to adapt based on emerging data.

• Funding and operational readiness are the main gating factors for launching pivotal studies.